TY - JOUR
T1 - Impact of differences in acute respiratory distress syndrome randomised controlled trial inclusion and exclusion criteria: systematic review and meta-analysis
AU - Saha, Rohit
AU - Assouline, Benjamin
AU - Mason, Georgina
AU - Douiri, Abdel
AU - Summers, Charlotte
AU - Shankar-Hari, Manu
N1 - Funding Information:
Wellcome Trust to CS; Medical Research Council to CS; National Institute of Health Research Cambridge Biomedical Research Centre to CS; National Institutes of Health to CS; British Heart Foundation to CS; GlaxoSmithKline to CS; AstraZeneca to CS; Bristol Myers Squibb to CS; National Institute of Health Research Clinician Scientist Award (NIHR-CS-2016-16-011) to MS-H.
Publisher Copyright:
© 2021 British Journal of Anaesthesia
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/7
Y1 - 2021/7
N2 - Background: Control-arm mortality varies between acute respiratory distress syndrome (ARDS) RCTs. Methods: We systematically reviewed ARDS RCTs that commenced recruitment after publication of the American–European Consensus (AECC) definition (MEDLINE, Embase, and Cochrane central register of controlled trials; January 1994 to October 2020). We assessed concordance of RCT inclusion criteria to ARDS consensus definitions and whether exclusion criteria are strongly or poorly justified. We estimated the proportion of between-trial difference in control-arm 28-day mortality explained by the inclusion criteria and RCT design characteristics using meta-regression. Results: A literature search identified 43 709 records. One hundred and fifty ARDS RCTs were included; 146/150 (97.3%) RCTs defined ARDS inclusion criteria using AECC/Berlin definitions. Deviations from consensus definitions, primarily aimed at improving ARDS diagnostic certainty, frequently related to duration of hypoxaemia (117/146; 80.1%). Exclusion criteria could be grouped by rationale for selection into strongly or poorly justified criteria. Common poorly justified exclusions included pregnancy related, age, and comorbidities (infectious/immunosuppression, hepatic, renal, and human immunodeficiency virus/acquired immunodeficiency syndrome). Control-arm 28-day mortality varied between ARDS RCTs (mean: 29.8% [95% confidence interval: 27.0–32.7%; I
2=88.8%; τ
2=0.02; P<0.01]), and differed significantly between RCTs with different PaO
2:FiO
2 ratio inclusion thresholds (26.6–39.9 kPa vs <26.6 kPa; P<0.01). In a meta-regression model, inclusion criteria and RCT design characteristics accounted for 30.6% of between-trial difference (P<0.01). Conclusions: In most ARDS RCTs, consensus definitions are modified to use as inclusion criteria. Between-RCT mortality differences are mostly explained by the PaO
2:FiO
2 ratio threshold within the consensus definitions. An exclusion criteria framework can be applied when designing and reporting exclusion criteria in future ARDS RCTs.
AB - Background: Control-arm mortality varies between acute respiratory distress syndrome (ARDS) RCTs. Methods: We systematically reviewed ARDS RCTs that commenced recruitment after publication of the American–European Consensus (AECC) definition (MEDLINE, Embase, and Cochrane central register of controlled trials; January 1994 to October 2020). We assessed concordance of RCT inclusion criteria to ARDS consensus definitions and whether exclusion criteria are strongly or poorly justified. We estimated the proportion of between-trial difference in control-arm 28-day mortality explained by the inclusion criteria and RCT design characteristics using meta-regression. Results: A literature search identified 43 709 records. One hundred and fifty ARDS RCTs were included; 146/150 (97.3%) RCTs defined ARDS inclusion criteria using AECC/Berlin definitions. Deviations from consensus definitions, primarily aimed at improving ARDS diagnostic certainty, frequently related to duration of hypoxaemia (117/146; 80.1%). Exclusion criteria could be grouped by rationale for selection into strongly or poorly justified criteria. Common poorly justified exclusions included pregnancy related, age, and comorbidities (infectious/immunosuppression, hepatic, renal, and human immunodeficiency virus/acquired immunodeficiency syndrome). Control-arm 28-day mortality varied between ARDS RCTs (mean: 29.8% [95% confidence interval: 27.0–32.7%; I
2=88.8%; τ
2=0.02; P<0.01]), and differed significantly between RCTs with different PaO
2:FiO
2 ratio inclusion thresholds (26.6–39.9 kPa vs <26.6 kPa; P<0.01). In a meta-regression model, inclusion criteria and RCT design characteristics accounted for 30.6% of between-trial difference (P<0.01). Conclusions: In most ARDS RCTs, consensus definitions are modified to use as inclusion criteria. Between-RCT mortality differences are mostly explained by the PaO
2:FiO
2 ratio threshold within the consensus definitions. An exclusion criteria framework can be applied when designing and reporting exclusion criteria in future ARDS RCTs.
KW - ARDS
KW - exclusion
KW - inclusion
KW - mortality
KW - randomised controlled trial
UR - http://www.scopus.com/inward/record.url?scp=85103545622&partnerID=8YFLogxK
U2 - 10.1016/j.bja.2021.02.027
DO - 10.1016/j.bja.2021.02.027
M3 - Review article
SN - 0007-0912
VL - 127
SP - 85
EP - 101
JO - British Journal of Anaesthesia
JF - British Journal of Anaesthesia
IS - 1
ER -